Search Within

Hematologic Malignancies Research

Formats
  1. Journal Article (1545)
  2. Meeting Abstract (1260)
  3. Review (76)
  4. Editorial (35)
  5. Book Section (32)
  6. Research Letter (26)
  7. Conference Paper (15)
  8. Correspondence (8)
  9. Guidelines (4)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3005)
  2. GSK Faculty (2450)
  3. Department of Medicine (2318)
  4. Hematologic Malignancies, Division of (2120)
  5. Sloan Kettering Institute Faculty (2052)
  6. Molecular Pharmacology and Chemistry Program Faculty (1632)

More Groups

People
  1. Michel Sadelain (586)
  2. David Scheinberg (502)
  3. Alexander Lesokhin (381)
  4. Carl Landgren (336)
  5. Renier Brentjens (286)
  6. Gabriela Chiosis (281)

More People

Years
  1. 2025 (64)
  2. 2024 (131)
  3. 2023 (175)
  4. 2022 (126)
  5. 2021 (154)
  6. 2020 (173)

More Years

Publications
  1. Blood (660)
  2. Cancer Research (117)
  3. Journal of Clinical Oncology (112)
  4. Clinical Lymphoma, Myeloma and Leukemia (84)
  5. Biology of Blood and Marrow Transplantation (80)
  6. Molecular Therapy (68)

More Publications

Publishers
  1. American Society of Hematology (700)
  2. Nature Publishing Group (375)
  3. Elsevier Inc. (291)
  4. American Association for Cancer Research (245)
  5. American Society of Clinical Oncology (116)
  6. Cell Press (116)

More Publishers

Results (3005)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Revealing the impact of structural variants in multiple myeloma
    Journal Article

    Rustad, E. H.; Yellapantula, V. D.; Glodzik, D.; Maclachlan, K. H.; Diamond, B.; Boyle, E. M.; Ashby, C.; Blaney, P.; Gundem, G.; Hultcrantz, M.; more...
    Blood Cancer Discovery (2020)

    Fulltext@MSK | Save
  • Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape– Driven relapse in multiple myeloma
    Journal Article

    de Larrea, C. F.; Staehr, M.; Lopez, A. V.; Ng, K. Y.; Chen, Y.; Godfrey, W. D.; Purdon, T. J.; Ponomarev, V.; Wendel, H. G.; Brentjens, R. J.; more...
    Blood Cancer Discovery (2020)

    Fulltext@MSK | Save
  • COVID-19 infections and clinical outcomes in patients with multiple myeloma in New York City: A cohort study from five academic centers
    Journal Article

    Hultcrantz, M.; Richter, J.; Rosenbaum, C. A.; Patel, D.; Smith, E. L.; Korde, N.; Lu, S. X.; Mailankody, S.; Shah, U. A.; Lesokhin, A. M.; more...
    Blood Cancer Discovery (2020)

    Fulltext@MSK | Save
  • Duration of post-autologous hematopoietic cell transplant anemia and thrombocytopenia are associated with prolonged hospital length-of-stay for multiple myeloma patients
    Meeting Abstract

    Zheng-Lin, B.; Krishnamurthi, N.; Diamond, B.; Maclachlan, K. H.; Maura, F.; Landgren, O.; Chung, D. J.
    Blood (2020)

    Fulltext@MSK | Save
  • NOTCH and CAR signaling control T cell lineage commitment from pluripotent stem cells
    Meeting Abstract

    Van der Stegen, S.; Lindenbergh, P.; Petrovic, R.; Whitlock, B.; Clarke, R.; Valamehr, B.; Riviere, I.; Sadelain, M.
    Blood (2020)

    Fulltext@MSK | Save
  • VRd versus KRd safety profiles in newly diagnosed multiple myeloma patients using real-world evidence data from a single institution: VRd has high rates of chronic neuropathy, and KRd has low rates of cardiopulmonary or renal toxicities when using optimized IV fluid management coupled with baseline cardiac workup
    Meeting Abstract

    Tan, C.; Diamond, B.; Hultcrantz, M.; Korde, N.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Shah, U. A.; Lu, S. X.; Patel, D.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • The tumor associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B-cell lymphoma
    Meeting Abstract

    Takata, K.; Chong, L. C.; Ennishi, D.; Thakur, A.; Healy, S.; Viganò, E.; Dao, T.; Nielsen, J. S.; Ben-Neriah, S.; Aoki, T.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders: A population based study including 94,579 cases and 368,348 matched controls
    Meeting Abstract

    Shah, U. A.; Rögnvaldsson, S.; Derkach, A.; Björkholm, M.; Turesson, I.; David, Y.; Hultcrantz, M.; Tan, C.; Hassoun, H.; Korde, N.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • A pilot study evaluating lenalidomide and CC-486 in combination with radiotherapy for patients with plasmacytoma (LENAZART study)
    Meeting Abstract

    Shah, U. A.; Werner, K.; Tavitian, E.; Devlin, S.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Tan, C.; Lu, S. X.; Smith, E. L.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Favorable outcomes among patients with T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era
    Meeting Abstract

    Robin, E. T.; Drill, E.; Batlevi, C. L.; Caron, P.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Intlekofer, A. M.; Joffe, E.; more...
    Blood (2020)

    Fulltext@MSK | Save